anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 250C. of at least about 10 cps or about 100 cps at a shear rate of 0. I/second. In a preferred embodiment, the viscosity at 25°C. is in the range of from about 80,000 cps to about 300,000 cps. H:\mdt\Interwoven\NRPortbl\DCC\MDT\6121494_1.doc - 18/4/17
BACKGROUND AND PURPOSE: Muscle atrophy and diaphragm dysfunction are common complication in patients with prolong mechanical ventilator (PMV) and is associated with increased rate of weaning failure and days of hospitalization. Electrical stimulation (ES) has been shown to be beneficial in patients with severe chronic heart failure and chronic obstructive pulmonary disease. The purpose of this study is to examine the effects of ES on skeletal muscle function, pulmonary mechanics and hospitalization outcomes in patients with PMV.

METHODS: Patients who have been on mechanical ventilator for more than 21 days will be recruited from respiratory care center (RCC). All subjects will be randomly assigned into three groups: ES in abdominal muscles (ES-Abd, n=30),ES in brachial biceps (ES-bicep, n=30) and sham group(Sham). Subjects in both groups will receive ES in muscles for 30 min/session, 2 sessions/day for 10 days with the same setting except area of ES. The muscle function will be assessed by skin-fold thickness and muscle strength. The pulmonary function will be assessed by: lung compliance, airway resistance, tidal volume, minute volume and maximal inspiratory pressure. The hospitalization outcome will be followed up until patients are discharged from RCC. The outcomes variables include: weaning rate and duration, mortality, days of ventilator, and length of RCC stay.
The invention relates to a formula of a traditional Chinese medicine for treating hair loss. The traditional Chinese medicine is prepared by the following traditional Chinese medicines in parts by weight: 15-45 parts of radix millettiae speciosae, 14-40 parts of humulus scandens, 4-32 parts of philippine flemingia root, 2-13 parts of rhizoma polygonati, 10-36 parts of poria cocos, 2-9 parts of Chinese wolfberry, 14-40 parts of gastrodia elata, 2-13 parts of polygala tenuifolia, 20-40 parts of malt, 20-40 parts of fructus setariae germinatus, 15-35 parts of tribulus terrestris, 4-12 parts of rhizoma acori graminei, 20-45 parts of Chinese yam, 20-45 parts of caulis polygoni multiflori, 18-42 parts of bighead atractylodes rhizome, 12-38 parts of fleece-flower root, 10-30 parts of Chinese angelica, 20-50 parts of black soybean and 15-35 parts of mulberry. The traditional Chinese medicine can be prepared into a pill or a decoction. The traditional Chinese medicine can be decocted in boiled water for oral administration, one preparation of the traditional Chinese medicine is taken for two times per day, one treatment course is 15 days, and the taking of the traditional Chinese medicine is not stopped until new hair grows. The traditional Chinese medicine formula has the effects of nourishing blood and restoring hair, and tonifying spleen and strengthening the middle warmer. The adopted Lingnan traditional Chinese herbal medicines such as the humulus scandens, the philippine flemingia root and the radix millettiae speciosae belong to qi-tonifying drugs, are mild in drug property, not warm and dry and fragrant in taste and easy to accept by people. The formula of the traditional Chinese medicine is used for treating the hair loss for years and has a certain effect on the treatment of the deficiency of five internal organs, and no adverse reaction is discovered.
PURPOSE:To obtain a base for sustained release suppository capable of retaining desired blood level for a long time while keeping characteristics of suppository and readily inserting, free from tackiness and capable of readily producing by combining fatty acid monoglycerides having different carbon numbers. CONSTITUTION:The objective base for suppository containing one or two or more kinds of mixture of a 14-18C fatty acid monoglyceride (e.g. myristic acid monoglyceride or palmitic acid monoglyceride) and one or two or more kinds of mixture of a 10-12C fatty acid monoglyceride (e.g. capric acid monoglyceride or lauric acid monoglyceride) at a ratio of about 20-40wt.%:2-10wt.% and consisting of greasy base. Further, the water soluble base such as polyethylene glycol or propylene glycol is preferably added to the base at an amount of about 0.5-10wt.%. In the sustained release suppository using the base, blood level can be quickly raised and the base can not be administered only from the anus but also from the vagina.
The majority of attempts to quit smoking end in failure due to unpleasant withdrawal symptoms. One such symptom is sleep disturbances. Bupropion, effective in assisting with smoking cessation, commonly causes sleep disturbances as a medication side effect. In addition, a number of NRTs also cause sleep disturbances. This study will aim to characterize the effect of smoking cessation and smoking cessation treatments on sleep by measuring central and autonomic nervous system arousal. The study will also evaluate the impact of smoking cessation treatments on daytime sleepiness and mood as well as their effect on smoking relapse.

Participants will be randomly assigned to one of four groups. Participants will receive either bupropion (150 mg for 3 days and 300 mg for 60 days) or placebo, starting one week prior to smoking quit day. They will then receive either active NRT (21 mg for 6 weeks, 14 mg for 1 week, and 7 mg for 1 week) or placebo, starting on quit day. Participants will be studied for up to 5 nights in a sleep lab. Sleep studies will include polysomnography measurements, including electrooculography of both eyes, activity of mentalis muscle and both anterior tibialis muscles, EEG, ECG, oxygen saturation, airflow, and respiratory efforts. Sleep studies will occur on the 2 nights prior to quit day, the quit night, and the 2 nights after quitting. Each sleep study will be followed by daytime measures. These will include a series of self-report instruments, sleepiness and performance measures, and physiological activity measures. Carbon monoxide levels will also be a daytime measurement and must fall below 10 ppm on the post quit days. All participants will receive bimonthly phone counseling for 12 months, starting on quit day. Participants will have follow-up evaluations at Months 3 and 12 in order to measure carbon monoxide levels and complete self-report instruments.
<P>PROBLEM TO BE SOLVED: To provide an orally disintegrable tablet having persistency of flavor, excellent in masking-retaining effect on medicine odor and not leaving unpleasant lingering scent feeling which is characteristic to a medicine in oral cavity/nasal cavity also after disintegrating the tablet in the oral cavity and then swallowing the tablet.  <P>SOLUTION: The orally disintegrable tablet is obtained by formulating a medicine with flavor particles in which an essential oil is carried on gum arabic. In the tablet, an essential oil containing an ester such as litchi oil or an essential oil containing a limonene such as lemon oil is preferably used. The unpleasant lingering scent in the oral cavity/nasal cavity can be suppressed by adding a sugar alcohol as a tablet component together with the flavor particles or adding a sweetening agent having high sweetness such as an organic acid (salt) e.g. citric acid or aspartame.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
1,243,321. 4 - Aminomethylbicycloheptane carboxylic acid derivatives. MERCK & CO. Inc. 1 Jan., 1970 [13 June, 1969], No. 89/70. Addition to 1,209,799. Heading C2C. Novel compounds of Formula I and alkanoylamino esters and salts thereof wherein X is H 2  or 0 are prepared by reduction of a compound of Formula II  wherein Y is H 2  or -O-CH 2 -CH 2 -O followed if necessary by hydrolysis of the ketal groups to give the ketone and optionally followed by alkanoylation or ester or salt formation. Pharmaceutical compositions having antifibrinolytic activity being in conventional forms for oral and parenteral administration comprise an above novel compound or derivative and a carrier therefor.
The invention discloses a drug for treatment of male infertility. A preparation method of the drug for treatment of male infertility comprises the following steps of adding rehmanniae radix, prepared rehmannia root, fleece-flower root, Chinese angelica, ginseng, cornus officinalis, chinaroot greenbrier rhizome, asparagus tuber, tuber of dwarf lilyturf, cyathula root, semen cuscutae, Chinese magnoliavine, phellodendron, wolfberry and raspberry into water, decocting the mixture to obtain soup, concentrating the soup, adding conventional auxiliary materials into the concentrated soup, adding purified water into the soup containing the auxiliary materials until crude drug content reaches 1g/ml, and carrying out potting and disinfection to obtain an oral liquid preparation. The drug for treatment of male infertility has the effects of nourishing yin and invigorating the kidney, and tonifying qi and strengthening yang. The drug for treatment of male infertility has special effects of treatment of male infertility. The drug for treatment of male infertility is natural and safe and does not have toxic and side effects. Through clinical observation, an effective rate of the drug for treatment of male infertility is 86%.
Crosslinking compositions are disclosed. In various embodiments, the crosslinking composition comprises the reaction product of: a first siloxane having at least one pendant polycyclic anhydride group; a second siloxane having at least one pendant polycyclic anhydride group; and a polyol having at least two hydroxyl groups reactive with said pendant polycyclic anhydride groups of said first and second siloxanes. Personal care compositions are also provided. The personal care composition comprises a cross-linking composition having at least two carboxyl groups. In various embodiments, the crosslinking composition is as described above. The personal care composition additionally comprises at least one cosmetic component; optionally in a cosmetically acceptable medium. Methods of forming the crosslinked compositions and the personal care compositions are also disclosed. Also disclosed are polycyclic anhydride compositions and polyorganosiloxane compositions.
ERTACZO (sertaconazole nitrate) cream, 2%, is for topical application. It contains the azole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.

Sertaconazole nitrate is designated chemically as (±)-1-[2,4-dichloro-β-[(7-chlorobenzo-[b]thien-3-yl)methoxy]phenethyl]imidazole nitrate. It has a molecular weight of 500.8. The molecular formula is C20H15Cl3N2OS ● HNO3, and the structural formula is as follows:

Sertaconazole nitrate is a white or almost white powder. It is practically insoluble in water, soluble in methanol, and sparingly soluble in alcohol and in methylene chloride. Each gram of ERTACZO cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base of ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, purified water, and sorbic acid.
Chronic obstructive pulmonary disease (COPD) is a common lung disease that impairs airflow and causes breathing difficulties. COPD is a major contributor to chronic health issues and mortality globally; it ranked as the third leading cause of death worldwide, resulting in 3.23 million fatalities in 2019. Individuals with COPD typically develop lung damage or airway obstruction. This condition is characterized by several common symptoms, including coughing, phlegm production, difficulty breathing, wheezing, and fatigue. The challenge in breathing frequently leads to reduced exercise endurance and diminished daily activity levels, which negatively affects health-related quality of life (HRQL). Despite following the optimal treatment provided by the Global Initiative for chronic obstructive lung disease (GOLD) guidelines, patients with COPD still experience significant disease effects. This underscores the need for continued research on potential therapies for COPD.

COPD is a gradually progressive airway disease. Harmful agents such as cigarettes and infection are the primary risk factor for COPD. The development of COPD involves airway inflammation and damage to the lung tissue. Persistent exposure to harmful agents damages lung epithelial cells, playing a crucial role in the pathogenesis of COPD. During this process, damage-associated molecular patterns (DAMPs) are released, triggering inflammatory pathways and the release of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-α. These cytokines further activate inflammatory cells, such as macrophages and neutrophils, leading to further damage to lung tissues. These inflammatory mechanisms offer insights into potentially effective treatments.

Jing Si Herbal Tea (JSHT) is a herbal blend formulated to regulate the immune system and treat inflammatory respiratory conditions. A recent study showed that combining JSHT with standard treatment in patients with COVID-19 improved clinical C-reactive protein levels and alleviated infections more effectively than standard treatment alone. Additionally, using JSHT decreases the risk of intubation, critical conditions, and mortality. This suggests that JSHT may be a beneficial adjunct therapy for patients with COVID-19. However, the therapeutic effects of JSHT in COPD have not yet been studied.

Given that JSHT was designed for immune regulation and treatment of inflammatory diseases, investigators hypothesized that JSHT could be beneficial for patients with COPD. Therefore, investigators study the therapeutic effects and precise mechanisms of action of JSHT in COPD. This study provides a possible strategy for using JSHT as an adjuvant therapy for COPD.
Patients will receive a nerve block of the radial, median, and ulnar nerves at the level of the forearm using 1% lidocaine with epinephrine. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
Preoperative: Cardenilimab was administered at a dose of 10 mg/kg intravenously once daily, with one cycle every 21 days, for a total of 4 cycles. Lenvatinib was prescribed as follows: for patients weighing less than 60 kg, 8 mg was given orally once daily for 4 cycles; for those weighing more than 60 kg, 12 mg was administered orally once daily for a total of 4 cycles. Surgery: The patient underwent standard radical nephrectomy 30 to 40 days after completing the 4 cycles of lenvatinib treatment. Postoperative: Cardenilimab was continued at a dose of 10 mg/kg intravenously once daily, with one cycle every 21 days, for a total of 8 cycles. Lenvatinib dosing postoperatively was as follows: for patients weighing less than 60 kg, 8 mg was given orally once daily for a total of 8 cycles; for those weighing more than 60 kg, 12 mg was administered orally once daily for a total of 8 cycles.
This study extends the assessment of brain connectivity and function, being conducted in the Human Connectome Project (HCP), to psychiatrically ill populations. The HCP consortium has made significant improvements in MRI instrumentation, data acquisition, preprocessing, and analysis. These improvements are currently providing publicly available data on the structure, function, and connectivity of young adult human (age 22-35) brains at unprecedented spatial resolution, temporal resolution, and accuracy. This study will focus on individuals aged 18-40 years who have a diagnosis of either schizophrenia/schizoaffective disorder or bipolar disorder, or are healthy controls. Additionally, similar to the HCP, the investigator will study the effect of genetics on the patterns of brain connectivity in various psychiatric populations. DNA will be collected non-invasively from saliva. Furthermore, this investigator will study cortisol levels in hair samples as an additional assessment to help characterize brain imagining findings.
Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
1. Technical Result Obtaining powdered composition having stable dispersibility.         2. Essence A composition comprises an active material and pharmaceutically-acceptable matrix, which exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 100C and the composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution.         3. Field of Application Pharmacology.
The purpose of this study is to assess whether patients will execute an advance directive which offers a limited trial of life-sustaining therapy in non-terminal illness, declines life-sustaining therapy or artificial nutrition in advanced dementia, or declines life-sustaining therapy in general. Advance directives (ADs) as currently drafted have been questioned since they have not had much effect on end-of-life care. However, the reason for the lack of success may be simply that they rarely apply. Traditional ADs, which are limited to terminal illness or persistent vegetative states, are difficult to apply to the more common cases of critical illness in the setting of potentially reversible disease and advanced dementia, which are often not recognized as terminal. In addition, terminal ADs are drafted too narrowly for patients who do not wish for life-sustaining therapy regardless of condition.

Patients may execute either AD at the conclusion of the survey. This research has the potential to demonstrate widely reproducible methods on which more precise advance planning can be based and thereby improve end-of-life care.
PURPOSE:To supply water, etc., and to raise erythrocyte deformation ability, comprising a filtrate prepared by filtering an acetic acid fermentation solution of a raw material consisting of rice bran, rice and water, a concentrated solution or a dried material thereof, water and fruit juice as essential components. CONSTITUTION:Raw material race is wall washed, immersed in water for 24 hours, boiled, cooled, incorporated with seed KOJI and KOJI is produced in a KOJI manufacturing machine for about 70 hours at about 32 deg.C to sufficiently attach spores. Pots for brewing are successively charged with KOJI, boiled rice and underground water for brewing, finally KOJI is sprinkled in the pots, the pots are arranged in the open air and the boiled rice is fermented under a natural condition. The fermented substance is aged, filtered and sterilized at about 80 deg.C for about 30 minutes to give a product. Then the filtrate, a concentrated solution or a dried substance of the filtrate, water or a solution of salt and fruit juice are used as essential components to prepare a sport drink agent. The drink agent can be blended with saccharides, vitamins, etc., besides the essential components.
Obesity and overweight are the major risk factors for numerous chronic diseases, including cardiovascular diseases such as heart disease and stroke, which are the leading causes of death worldwide. The prevalence of obesity has dramatically risen in both developed and developing countries, making it a significant public health concern and a global crisis. Despite lifestyle modifications being the first-line treatment, the high risk of relapse has led to a growing interest in non-invasive pharmacotherapeutic interventions to achieve and maintain weight loss and reverse the growth of the obesity epidemic. Cardiovascular diseases and cancer account for the highest mortality rates among other comorbidities associated with obesity and overweight. Excess and abnormally deposited adipose tissue secretes various inflammatory mediators, leading to cardiovascular diseases and cancers. Weight loss of 5-10% significantly reduces cardiometabolic risk. Medications currently approved in the USA for long-term management of obesity are orlistat, naltrexone, bupropion, phentermine/topiramate, and Glucagon Like Peptide-1 (GLP-1) agonists such as liraglutide and semaglutide. The benefit-to-risk of medications, comorbidities, and individual responses should guide the treatment decisions. The article provides a comprehensive overview and discussion of several weight loss medications used previously and currently, including their efficacy, mechanisms of action, and side effects.
Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
BACKGROUND: Toxic anterior segment syndrome (TASS) is a rare, noninfectious inflammation that occurs after anterior segment surgery. We report a case herein that developed presumed atypical late-onset TASS after V4c implantable collamer lens (ICL) implantation surgery.
CASE PRESENTATION: A 26-year-old man underwent ICL implantation surgeries of both eyes on two separate days. The 1-day and 7-day postoperative routine follow-up visits revealed no abnormalities. However, one month after surgery, dense white spots attached to the posterior surface and scattered ones to the anterior surface of ICL in the left eye were noted on anterior segment examination. His uncorrected distance visual acuity (UDVA) was 20/16 in both eyes and the fundus examination was normal. Despite the absence of typical clinical manifestations, late-onset TASS was suspect and intense topical steroid was administered. After 6 weeks of tapering topical steroid therapy, the white spots disappeared and the patient had no subjective complains throughout the treatment period.
CONCLUSIONS: This case suggested that the traditionally considered acute and serious TASS could also present as delayed and insidious onset after ICL implantation surgery. Due to its variabilities, the awareness of TASS should be raised to ophthalmologists and regular follow-up visits should be emphasized to patients. Once TASS was suspected, intensive steroid therapy should be implemented in time.